Scancell Holdings Plc Presents Moditope Data at Immunotherapy Conference
September 11 2017 - 1:01AM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
11 September 2017
11 September 2017
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell Presents Moditope(R) Data at the Third
CRI-CIMT-EATI-AACR International Cancer Immunotherapy
Conference
Scancell Holdings plc, ('Scancell' or the 'Company') the
developer of novel immunotherapies for the treatment of cancer,
announces that it has presented data on the Company's Moditope(R)
platform at the Third CRI-CIMT-EATI-AACR International Cancer
Immunotherapy Conference in Mainz, Germany, 6-9 September 2017.
Scancell's Moditope(R) platform stimulates powerful anti-tumour
T-cell responses against citrullinated peptides which destroy
tumours without toxicity.
Prof. Lindy Durrant, Ph.D., Chief Scientific Officer of Scancell
and Professor of Cancer Immunotherapy, University of Nottingham,
presented two posters on Friday 8 September 2017 at 6.15pm CET, in
poster session B.
Prof. Durrant commented:
"We were pleased to be selected to present our latest data on
Moditope(R) at this year's prestigious International Cancer
Immunotherapy Conference, showing that our lead product from the
Moditope(R) platform, Modi-1, induced strong anti-tumour immunity
in pancreatic, lung, ovarian and melanoma models with up to 100%
survival.
"Our poster in collaboration with ISA Pharmaceuticals showed
that Modi-1 conjugated to synthetic TLR1/2 agonists generated an
anti-tumour response at up to 100-fold lower doses than Modi-1
alone and that these conjugated peptides induced a memory response
against tumour re-challenge.
"These results suggest that Modi-1 conjugated directly to TLR
agonists could be a powerful new approach to the treatment of
cancer."
Both posters will be made available on the Investor section of
the Company's website:
https://www.scancell.co.uk/investors
For Further Information:
Dr John Chiplin, Executive
Chairman +1 858 900 2646
Dr Richard Goodfellow, Scancell Holdings +44 (0) 20 3727
CEO Plc 1000
Freddy Crossley (Corporate
Finance)
Tom Salvesen (Corporate Panmure Gordon +44 (0) 20 7886
Broking) & Co 2500
+44 (0) 20 3727
Mo Noonan/Simon Conway FTI Consulting 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
Scancell's first ImmunoBody(R), SCIB1 is being developed for the
treatment of melanoma. Data from the Phase 1/2 clinical trial
demonstrate that SCIB1, when used as monotherapy, has a marked
effect on tumour load, produces a melanoma-specific immune response
and highly encouraging survival trend without serious side effects.
In patients with resected disease there is increasing evidence to
suggest that SCIB1 may delay or prevent disease recurrence.
Scancell's ImmunoBody(R) vaccines target dendritic cells and
stimulate both parts of the cellular immune system: the helper cell
system where inflammation is stimulated at the tumour site and the
cytotoxic T-lymphocyte or CTL response where immune system cells
are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and
checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune
checkpoint pathways) have shown enhanced tumour destruction and
significantly longer survival times than when either treatment was
used alone. Experimental data suggests that the high avidity T
cells induced by ImmunoBody(R) vaccines increase expression of
PDL-1 on the tumour cell surface, thereby making the tumours more
sensitive to checkpoint inhibitor drugs. Re-challenging animals
with tumour cells after SCIB1 treatment resulted in 100% survival
suggesting that ImmunoBody(R) induces a powerful memory response.
Such an effect has not been observed with checkpoint
inhibitors.
Scancell has also identified and patented a series of modified
epitopes that stimulate the production of killer CD4+ T cells that
destroy tumours without toxicity. The Directors believe that the
Moditope(R) platform could play a major role in the development of
safe and effective cancer immunotherapies in the future.
About the CRI-CIMT-EATI-AACR International Cancer Immunotherapy
Conference
The Cancer Research Institute (CRI), the Association for Cancer
lmmunotherapy (CIMT), the European Academy of Tumor Immunology
(EATI), and the American Association for Cancer Research (AACR) are
proud to join forces once again to sponsor the Third International
Cancer lmmunotherapy Conference.
The 2017 meeting will take place at the Rheingoldhalle Congress
Center in Mainz/Frankfurt, Germany from September 6-9, 2017. The
program will focus on "Translating Science into Survival," and
feature talks from more than 60 leaders in the field covering all
areas of inquiry in cancer immunology and immunotherapy, including:
neoantigens and vaccines, novel mechanisms of immunosuppression and
immune evasion, biomarkers, microbiota, oncolytic viruses, new
agents and their mode of action, combination therapies, adoptive
cell therapies, new checkpoints, non-checkpoint immunotherapies,
and the tumour microenvironment.
This meeting will provide an unparalleled opportunity for
teaching, learning, and networking among all stakeholders in the
field: scientists, clinicians, regulators, drug developers, and
patient advocates.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSLFDUFWSEFU
(END) Dow Jones Newswires
September 11, 2017 02:01 ET (06:01 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024